Phase II Clinical testing of trabectedin after platinum therapy in patients with non-small cell lung cancer with advanced over-expresion of XPG and / or ERCC1, and subexpresion of BRCA1 [Ensayo Clinico de Fase II de Trabectedina tras Progresion a Terapia Antitumoral basada en Platino en Pacientes con Cancer No Microcitico de Pulmon (CNMP) Avanzado con Sobreexpresion de XPG y/o ERCC1, y Subexpresion de BRCA1]

Trial Profile

Phase II Clinical testing of trabectedin after platinum therapy in patients with non-small cell lung cancer with advanced over-expresion of XPG and / or ERCC1, and subexpresion of BRCA1 [Ensayo Clinico de Fase II de Trabectedina tras Progresion a Terapia Antitumoral basada en Platino en Pacientes con Cancer No Microcitico de Pulmon (CNMP) Avanzado con Sobreexpresion de XPG y/o ERCC1, y Subexpresion de BRCA1]

Recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Aug 2011

At a glance

  • Drugs Trabectedin (Primary)
  • Indications Non-small cell lung cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms STRACT
  • Sponsors PharmaMar
  • Most Recent Events

    • 30 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top